Academic Journal
57MO First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2− advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial
| العنوان: | 57MO First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2− advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial |
|---|---|
| المؤلفون: | Yap, Y-S., Im, S-A., Lu, Y-S., Azim, H.A., Eralp, Y., Kanakasetty, G.B., Abdel-Razeq, H., Zhukova, L., Thuerigen, A., Delgar Alfaro, T., Wu, J., Gao, M., El Saghir, N.S. |
| المصدر: | Annals of Oncology ; volume 34, page S1488 ; ISSN 0923-7534 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2023 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/j.annonc.2023.10.192 |
| الاتاحة: | http://dx.doi.org/10.1016/j.annonc.2023.10.192 https://api.elsevier.com/content/article/PII:S0923753423043983?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S0923753423043983?httpAccept=text/plain |
| Rights: | https://www.elsevier.com/tdm/userlicense/1.0/ |
| رقم الانضمام: | edsbas.C66E01E7 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.annonc.2023.10.192 |
|---|